Literature DB >> 18752718

Treatment of bipolar disorder: a systematic review of available data and clinical perspectives.

Konstantinos N Fountoulakis1, Eduard Vieta.   

Abstract

This paper is a systematic review of the available data concerning the treatment of bipolar disorder: a systematic Medline search concerning treatment guidelines and clinical trials. The search for treatment guidelines returned 583 articles and 913 papers for RCTs. The search was last performed on 1 March 2008. An additional search included repositories of clinical trials and previous systematic reviews in order to trace especially older trials. The literature suggests that lithium is useful during the acute manic and the maintenance phase. Both first- and second-generation antipsychotics are efficacious in the treatment of acute mania. Quetiapine and the olanzapine-fluoxetine combination are also effective for treating bipolar depression, while olanzapine, quetiapine and aripiprazole are effective during the maintenance phase. Anticonvulsants, particularly valproate and carbamazepine have antimanic properties, whereas lamotrigine may be preferably effective in the treatment of depression but not mania. Antidepressants should always be used in combination with an antimanic agent because they were reported to induce switching to mania or hypomania, mixed episodes, and rapid cycling when given as monotherapy. The best evidence-based psychosocial interventions for bipolar disorder are group- and family-focused psychoeducation. Electroconvulsive therapy is an option for refractory patients. Although a variety of treatment options for bipolar disorder is currently available, their effectiveness is far from satisfactory, especially against bipolar depression and maintenance. Combination therapy may improve treatment outcome but it also carries the burden of more side-effects. Further research as well as the development of better guidelines and algorithms for step-by-step rational treatment are necessary.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752718     DOI: 10.1017/S1461145708009231

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  21 in total

1.  Psychosocial predictors of mood symptoms 1 year after acute phase treatment of bipolar I disorder.

Authors:  Lauren M Weinstock; Ivan W Miller
Journal:  Compr Psychiatry       Date:  2010-03-12       Impact factor: 3.735

2.  Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers.

Authors:  Marie Tournier; Bernard Bégaud; Audrey Cougnard; Guy-Robert Auleley; Jean Deligne; Claudine Blum-Boisgard; Anne C M Thiébaut; Hélène Verdoux
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

Review 3.  Cognitive effects of second-generation antipsychotics: current insights into neurochemical mechanisms.

Authors:  Fabio Fumagalli; Angelisa Frasca; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 4.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

5.  Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report.

Authors:  Martha Sajatovic; Ariel Gildengers; Rayan K Al Jurdi; Laszlo Gyulai; Kristin A Cassidy; Rebecca L Greenberg; Martha L Bruce; Benoit H Mulsant; Thomas Ten Have; Robert C Young
Journal:  Bipolar Disord       Date:  2011-05       Impact factor: 6.744

Review 6.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

7.  Comparison of Sexual Function and Hormonal Parameters Between Mood Stabilizer Treatment Modalities in Bipolar Disorder.

Authors:  Sermin Kesebir; Burak Toprak; Burak Baykaran; Aytül Hariri; Mustafa Bilici
Journal:  Noro Psikiyatr Ars       Date:  2014-09-01       Impact factor: 1.339

8.  Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review.

Authors:  Konstantinos N Fountoulakis; Eduard Vieta
Journal:  Ann Gen Psychiatry       Date:  2009-07-27       Impact factor: 3.455

9.  Aging changes and medical complexity in late-life bipolar disorder: emerging research findings that may help advance care.

Authors:  Martha Sajatovic; Brent P Forester; Ariel Gildengers; Benoit H Mulsant
Journal:  Neuropsychiatry (London)       Date:  2013-12-01

10.  Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole.

Authors:  David J Muzina
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.